Tempus AI, Inc. (NASDAQ: TEM) reported preliminary, unaudited financial results for Q4 and full year 2025, showcasing impressive growth in revenue streams and key business areas.
The company's notable revenue growth of approximately 83% year-over-year in 2025 was primarily driven by a significant surge in Diagnostics revenue, up by about 111%, particularly fueled by expansions in Oncology and Hereditary volume areas.
Additionally, the Data and applications revenue witnessed a substantial increase of around 31% in 2025, indicating Tempus' strong performance and potential in the market.
Revenue Growth
Tempus achieved a revenue milestone of approximately $1.27 billion in 2025, marking a remarkable 83% year-over-year growth, with organic growth excluding Ambry contributing around 30% to the overall increase.
Diagnostics Expansion
The robust growth in Diagnostics revenue, reaching approximately $955 million, showcased a remarkable surge of around 111%, propelled by significant expansions in Oncology and Hereditary volume segments.
Data Business Growth
The Data and applications revenue surged to approximately $316 million in 2025, reflecting a notable 31% growth, particularly driven by a significant rise of about 38% in Insights revenue.
- The exceptional performance in both revenue streams positions Tempus strongly for further growth in 2026, indicating the company's resilience and market competitiveness.
- Eric Lefkofsky, Tempus' CEO, emphasized the exceptional growth in the genomics and data licensing sectors, signifying the company's strategic focus on innovative and high-growth areas.
- The promising trajectory of Tempus' AI-driven products across all sectors underscores the company's potential for sustained growth and market leadership in the future.
Tempus anticipates continued strong financial performance in 2025, laying a solid foundation for sustained growth in 2026. The company's strategic emphasis on precision medicine and AI technology positions it favorably for future success, reflecting a robust growth trajectory and market potential.